Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1461
- Registration Number
- NCT00281580
- Locations
- 🇲🇽
1235.1.203, Col. Magdalena de las Salinas, Mexico
🇲🇽1235.1.208 "Ignacio Chávez", mexico DF, Mexico
🇲🇽1235.1.211 Obesidad Y Prevencion de Enfermedades, Mexico, D.F., Mexico
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)
- Conditions
- Arthritis, Juvenile Rheumatoid
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 226
- Registration Number
- NCT00279747
- Locations
- 🇦🇹
Univ.-Klinik für Kinder- und Jugendheilkunde Wien, Wien, Austria
🇦🇹Gottfried Preyersches Kinderspital d. Stadt Wien, Wien, Austria
🇧🇪UZ Gent, Gent, Belgium
Spiriva® Assessment of FEV1 (SAFE)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 914
- Registration Number
- NCT00277264
- Locations
- 🇨🇦
Penticton Regional Hospital, Penticton, British Columbia, Canada
🇨🇦220 Royal Avenue, New Westminster, British Columbia, Canada
🇨🇦825 Coxwell Avenue, Toronto, Ontario, Canada
Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 346
- Registration Number
- NCT00275457
- Locations
- 🇦🇹
Univ.-Klinik für Neurologie, Innsbruck, Austria
🇸🇪Boehringer Ingelheim Investigational Site, Örebro, Sweden
🇦🇹Confraternität Privatklinik, Wien, Austria
3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
- Conditions
- HIV Infections
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 216
- Registration Number
- NCT00275444
- Locations
- 🇺🇸
Mercer University School of Medicine, Macon, Georgia, United States
🇺🇸John's Hopkins University, Baltimore, Maryland, United States
🇺🇸Rush-Presbytarian-St Luke's Medical Center, Chicago, Illinois, United States
A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT00274534
- Locations
- 🇺🇸
Hunter Holmes McGuire Medical Center, Richmond, Virginia, United States
🇺🇸Hines Veterans Administration Hospital, Hines, Illinois, United States
Tiotropium (Spiriva) Rehabilitation Study
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 108
- Registration Number
- NCT00274521
- Locations
- 🇺🇸
Harbor-UCLA Research and Education Institute, Torrance, California, United States
🇺🇸St. Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM
- Conditions
- Hypertension
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 801
- Registration Number
- NCT00274612
- Locations
- 🇦🇹
Rehabilitationszentrum für Herz- und Kreislauferkrankungen, Bad Tatzmannsdorf, Austria
🇦🇹Landeskrankenhaus Graz West, Graz, Austria
🇦🇹Univ.-Klinik für Innere Medizin III, Wien, Austria
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1829
- Registration Number
- NCT00274547
- Locations
- 🇺🇸
Boehringer Ingelheim Investigational Site, Salt Lake City, Utah, United States
🇺🇸Hampton VA Medical Center, Hampton, Virginia, United States
🇺🇸Carl T. Hayden VA Medical Center, Phoenix, Arizona, United States
Headache Study to Compare Aggrenox Full Dose and Reduced Dose
- Conditions
- Cerebrovascular Accident
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 100
- Registration Number
- NCT00274586
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taipei, Taiwan